Worldwide Clinical Nutrition Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2025

Market Research Future published a Cooked  research report on “Global Clinical nutrition MarketResearch Report - Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.

 Clinical Nutrition Market-Overview

Clinical nutrition mainly focuses on the development of nutritional products especially for the patients suffering from chronic diseases such as diabetes, chronic obstructive pulmonary disease, gastrointestinal disorders, cancer, immune system disorders, liver and kidney diseases, and many more. Rising prevalence of chronic diseases, extensive demand for clinical nutrition therapy, and growing awareness about the use of nutritional products drive the growth of the market. Additionally, the prevalence of lifestyle diseases such as obesity, and addiction to smoking and alcohol also stimulate the market growth. The market is expected to show flourishing growth in developing regions of Asia Pacific owing to a rising economic burden of chronic diseases and increasing demand for nutritional supplements. Clinical nutrition is now becoming an important field of interest, due to increase important of nutrition to be provided to the patient during his/her stay at the hospital as well as at home. Quality of products offered by the company determines the quality goals and efficiency that can be achieved so as to attract more and more customers, and increase in the sale of nutritional products. The products are needed to be manufactured through quality assurance and quality control market, thus sustaining the position in the market. Therefore, the company should strive to develop qualitative products to attract more and more customers, and enhance its growth.

Key players in the Clinical Nutrition Market:

Abbott (U.S.), AYMES Nutrition International Ltd. (U.K), NeoMed (U.S.), Baxter International (U.S.), Danone (France), B. Braun Melsungen AG (Germany), Mead Johnson & Company, LLC. (U.S.), Nestlé Health Science (Switzerland), Nutricia Advanced  Clinical nutrition (Netherland), Primus Pharmaceuticals (U.S.), Inc., Solace Nutrition (U.K) and others. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population.

Key Developments:

Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap. The companies develop number of nutritional products for patients, addressing their according to the disease condition. 

Danone:

• Danone is a French multinational food-products company in France. The company introduced, SYNEO which is the first and only hypoallergenic formula containing prebiotics as well as probiotics for the infants suffering from cow’s milk allergy, multiple food allergies, and related gastrointestinal conditions.

Nestlé Health Science:

• In October, 2015, Nestlé Health Science has announced its collaboration with GE Healthcare to improve nutrition monitoring for critically-ill patients. RESOURCE, BOOST, PRONOURISH are some of the major product of the company.
• Nestlé Health Science has acquired Vitaflo headquartered in UK to establish a foothold in the fast-growing market for uniquely formulated products. It has 2nd largest market in US and 1st in Canada.
• In 2015, Nestlé Health Science acquired Phagenesis, a UK-based company developing Phagenyx, an innovative pharyngeal electrical stimulation device to treat dysphagia.
• In July, 2015: Nestlé Health Science signed with Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) an exclusive agreement outside the United States and Canada for in the fields of Clostridium difficile infections and Inflammatory Bowel Disease (IBD).

Abbott Nutrition:

• Abbott manufactures, and sales enormous clinical nutrition products for adult, infant & new mother, infant & new mother, sports & active living, and therapeutic use. The company supplies these nutrition products under various brand names such as Similac, PediaSure, Pedialyte, Ensure, ZonePerfec, EAS, and Glucerna. The company focuses on healthy diabetes, malnutrition, and heart health.
• June, 2016: Abbott launched new EAS Protein Shakes, Powders and Bars especially for the Athletes with an aim of fuelling their Lifestyles, improving strength, and enhance their performance. The company strives to provide clinically proven nutrition for health-conscious individuals and athletes at every stage of their development, from beginner to professional.
• April, 2016: Abbott Launched EAS Myoplex Sports Nutrition Line for designed for performance. The product form new line are Myoplex Pre-Workout, Myoplex BCAA + Electrolytes, Myoplex Protein Blend, and Myoplex Micellar Casein.

Research in Clinical Nutrition by Key Players:

Abbott:  A research carried out by University of Illinois and Abbott at the Centre for Nutrition, Learning and Memory discovered that children with higher lutein levels in the eye tend to do better on tests of cognition and academic achievement. This help Abbot to understand the role of nutrition on childhood cognition, which will further help the company to develop product providing maximum benefits children enhancing their cognitive abilities.

Therefore, the market is driven by availability of numerous nutritional products, strategic approaches, and geographical expansion by key players. 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/global-clinical-nutrition-market-829

4D Printing in Healthcare Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2025

Market Overview

Global 4D Printing in Healthcare Market is expected to register a CAGR of 29.4% during the forecast period from 2019 to 2025 and expected to reach USD 30.4 Million by 2025.

In the past decade, there has been increasing use of 3D printing in the field of healthcare. The introduction of 4D printing and its shape-changing material property in the field of dentistry, implants, and prosthetics, among others will further enhance the 3D products used for these applications. The shape-changing property of the material used for 4D printing has been one of the major factors influencing the growth of the market.

Moreover, factors such as increasing research and development, rising investment by chemical companies. These chemical companies are keen on grabbing the opportunity for the development of smart materials in 4D printing, which in turn is directly enhancing the growth of the market.

Factors such as stringent regulatory policies for the approval of 4D printing medical devices market trends and limited skilled professionals have been major challenges for 4D printing in the healthcare market.  

Market Drivers

• Increasing application of 4D printing in healthcare verticals such as dentistry, implants, and prosthetics.
• The dental industry is one of the major applications of 4D printing. Clear aligners have been the most manufactured products via 3D printing in the dental industry.
• Align technology, the leader in global clear aligners market, accounts for about 80% of the market. The company uses 3D Systems to produce over 1.6 million custom aligners per week.
• Clear aligners can further be enhanced using 4D printing, as these products require shape altering properties according to the changing structure of the teeth on a weekly basis.
• 4D printers are also used to manufacture various dental implants, including dental implants, dentures, crowns, & bridges, among others.
• Increasing prevalence of dental diseases is further influencing the growth of the market. According to the MRFR research study in 2018, it was estimated that oral diseases affected more than 3.7 billion individuals that are around half of the world’s population.

• Rising research and development
• A research team from the US in March 2019, invented a new bio-ink that allows to print catalytically active live cells into several self-sustaining 3D geometries. These properties include tunable cell densities, fine filament thickness, and high catalytic productivity.

• Growing investment by chemical companies
• Various companies such as BASF Venture Capital GmbH and Evonik Venture Capital have invested in Chinese 3D printing companies

Market Challenges

• Stringent regulatory policies for the approval of 4D printing medical devices
• Limited skilled professionals

Segmentation

By Component

• Software & Services: Software and services accounted for the major market share in 2018. 3D printers have already been installed in numerous healthcare facilities across the globe. However, these machines would require updated software and also various services for the manufacturing of 4D products.

• Smart Material: Smart Material segment is expected to grow at the fastest growth rate due to continuous advancements for the materials in 4D printing. Investment by chemical companies for the development of smart material is further influencing the market growth.

By Technology

• Fused Deposition Modeling: Accounted for the largest market share due to its wide choice of raw materials and cost-effective process

• Direct Inkjet Cure: Expected to grow at the fastest growth rate majorly due to its dimensional accuracy, multi-material, and full-color printing properties

By Application

• Dental: accounted for the largest market share owing to the use of 4D printing for manufacturing of wide dental products including clear aligners, implants, and dentures among others

• Prosthetics: Expected to grow at the fastest growth rate due to increasing number of prosthetic procedures, accidental injuries, and sports injuries among others

By End-User

• Hospitals & Surgical Centers: Accounted for the leading market share owing to the increasing number of hospital & surgical centers. According to a study published by the American Hospital Association, there were 5,534 registered hospitals in the US in 2017.

• Dental Clinics & Laboratories (Offices): Use of 4D printing in dental clinics & laboratories, brings less complexity to existing procedures. Dental laboratories use 4D printing technologies that allow them to increase competitiveness and production, thus driving the growth of this segment.

By Region

• Americas: The Americas spearheaded the market in 2018 and is likely to continue to command during the assessment period. This is attributed to the existence of a large number of medical device companies, increasing research and development, and the presence of a large number of noticeable players engaged in manufacturing of 4D printing devices and software

• Europe: Reported for the second-largest share owing to increasing utilization of 3D & 4D printing in the field of healthcare. According to a study conducted in 2018, it was found that 65% of healthcare providers are implementing new printing technologies for medical products using custom made materials

• Asia-Pacific: The highest growth rate is attributed to the growing investment by government bodies and private & public companies. For instance, in November 2018, BASF Venture Capital GmbH invested in Chinese 3D printing company Prismlab.

Key Development

• In January 2019, Dentsply Sirona and Carbon announced a strategic collaboration to revolutionize digital denture materials. This strategic collaboration was announced to deliver denture materials for carbon digital 3D printing production solutions.

Key Players

• Stratasys Ltd (US)
• 3D Systems, Inc (US)
• EnvisionTEC (Germany)
• Poietis
• (France) 
• Organovo Holdings Inc. (US)
• Materialise NV (Belgium)
• Dassault Systèmes (France)  

Browse More Report Details @   https://www.marketresearchfuture.com/reports/4d-printing-healthcare-market-8630 

Global Meningococcal Vaccines Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2025

Market Forecast

Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.

Market Synopsis

Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.

The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).

Market Influencer

Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market Trends.

Market Drivers

• Rise in prevalence of the meningococcal disease
• According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
• Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
• Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
• Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
• Escalating positive results with the vaccines to boost the demand in the market
• Growing research and development activities by prominent players in the industry

Market Restraints

• Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.

Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.

In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.

Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.

By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes

Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.

Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.

By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.

UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.

Key Developments in the Global Meningococcal Vaccines Market

• In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years

• In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age

• In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B

Key Players

• Baxter international
• Pfizer Inc.
• Sanofi S.A.
• Novartis Pharmaceuticals Inc.
• JN-International Medical Corporation
• Serum Institute of India Ltd.
• GlaxoSmithKline
• BIO-MED
• Others

Browse more Details of the Report @ https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622

Cell Counting Market Likely Boost The Industry Revenue And Demand Till 2025

Market Highlights

According to MRFR analysis, Cell Counting Market is expected to register a CAGR of 5.8% during the forecast period of 2019 to 2025 and was valued at USD 8.47 Billion in 2018.

Cell counting is important for research and serves as one of the major steps in the majority of experiments. It is effectively utilized for maintaining cell cultures. Moreover, another important application of cell counting can be seen in the diagnosis of chronic diseases like cancer. For instance, an increase in the number of white blood cells (WBC) may indicate the possibility of cancerous growth in the body. Thus, cell counting is important for microbiology, hematology and other medical specialties.

The growth of the global cell counting market is determined by numerous factors such as increasing R&D expenditure, rising prevalence of cancer, and product launches. However, the high cost of devices and product recalls are projected to restrain the growth of the market during the forecast period.

The Global Cell Counting Market is currently dominated by several market players. The key players are involved in product launches, expansion, and strategic collaborations to strengthen their market positions. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.

Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share owing to the increase in the incidence of cancer and the presence of well-established pharmaceutical and biotechnology industry. The cell counting market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European cell counting market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cell counting market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the presence of a large patient pool and expansion of healthcare facilities, the market in Asia-Pacific is expected to be the fastest-growing. The cell counting market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Cell Counting Market has been segmented based on product, application, and end-user.

The market, based on type, has been divided into consumables and instruments. The consumable segment is likely to hold maximum market share in the global cell counting market. This due to the repeated purchase of the consumable compared with instrument products.

The global cell counting market based on application has been segregated into research application, clinical & diagnostic application, and others. The research application segment is anticipated to hold the largest share in the market due to the rising funding for stem cell research.
The end-user segments of the market are pharmaceutical and biotechnology companies, hospitals, research institutes, and others. The pharmaceutical and biotechnology companies’ segment is expected to hold the largest share of the market, as these are used cell counting products in research and development of new drugs and therapies.
Key Players

Some of the Key Players in the Global Cell Counting Market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Logos Biosystems, Inc. (South Korea), Olympus Corporation (Japan), Agilent Technologies, Inc. (US), PerkinElmer, Inc. (US), Sysmex Corporation (Japan), Abbott Laboratories (US), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-counting-market-8600 

Medical Drones Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Market Forecast

Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).

Market Synopsis

Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones market demand.

Medical Drones Market Size, In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.

How can this technology help in improving safety and care delivery?

• Bedside medication delivery
• Effective treatment from the distance
• Easy reach to an isolated place
• Pre-treatment facility till the time emergency service arrives at takeover

Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.

Market Influencer

Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.

Market Drivers

• Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions

• Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period

• Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players

Market Restraints

• Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.

Segmentation

By Application

• Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.

• Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.

• Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.

By End-User

• Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.

• Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.

By Region

• Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.

• Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.

• Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.

• Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.

Key Players

• DJI (China)
• DHL (Germany)
• Embention (Spain)
• Flirtey (US)
• Matternet (US)
• Vayu (US)
• Zipline (US)
• EHang (China)
• TUDelft (Netherlands)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-drones-market-8596 

Global Thalassemia Treatment Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2025

Market Forecast

Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.

Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.

Market Synopsis

Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.

Market Influencers

Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.

Market Drivers

• The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.

• Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.

• A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.

• The rise in demand for improved curative gene therapy is expected to drive the growth of the market.

Market Restraints

• Stringent regulatory policies
• High treatment costs

Segmentation

By Type

• Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.

• Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.

By Treatment

• Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.

• Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.

• Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.

• Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.

• Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.

By End-User

• Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.

• Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.

• Others: This segment includes research laboratories, educational institutes, among others.

By Region

• Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.

• Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.

• Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.

• Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.

Key Players

• Novartis AG (Switzerland)
• Bluebird Bio, Inc. (US)
• Kiadis Pharma (Netherlands)
• CELGENE CORPORATION (US)
• Sangamo Therapeutics (US)
• Acceleron Pharma, Inc. (US)
• Gamida Cell (Israel)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/thalassemia-treatment-market-8595

Cardiac Biomarkers Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2025

Market Forecast

Cardiac Biomarkers Market Size is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.

Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global Cardiac Biomarkers Diagnostics Market Trends. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.

Market Synopsis

Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.

Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.

The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.

Market Influencers

High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.

Market Drivers

• High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015
• Increasing adoption of outsourcing services
• Growing technological advancements:
• High spending by the pharmaceutical industry
• The increasing popularity of POC cardiac testing kits
• Increasing affordability for advanced cardiac treatments

Market Restraints

• Chances of false diagnosis of myocardial infarction
• High cost of the procedure
• Presence of other efficient methods for the diagnosis of cardiovascular diseases

Cardiac Biomarkers Market Segmentation

By Type

• Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours

• Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death

• Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction

• Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome

• Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.

By Location of Testing

• Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity

• Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment

By Application

• Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.

• Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles

• Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.

• Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis

By Region

• Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.

• Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.

• Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region

• Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.

Key Players

• Abbott Laboratories (US)
• ACS Biomarker (The Netherlands)
• BD (Becton, Dickinson and Company) (US)
• bioMérieux SA (France)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Hoffmann-La Roche Ltd (Switzerland)
• Johnson and Johnson (US)
• Quidel Corporation (US)
• Randox Laboratories Limited (UK)
• Siemens AG (Germany)
• Thermo Fisher Scientific, Inc. (US)
• Trivitron Healthcare Pvt. Ltd. (India)
• Novartis (Switzerland)

Browse More Report Details @   https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594